In a nutshell This trial is investigating the effectiveness of pembrolizumab (Keytruda) plus enzalutamide (Xtandi) in patients with prostate cancer. The primary outcome to be measured will be the absence of cancer on the prostate after it is surgically removed. This study is being conducted in Portland, OR. The details...
Read MoreProstate cancer Posts on Medivizor
What are the outcomes of sipuleucel-T treatment for patients with metastatic castration-resistant prostate cancer?
In a nutshell This study evaluated the safety and effectiveness of sipuleucel-T (Provenge) treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). The authors found that the average survival after sipuleucel-T treatment was 30.7 months and that 13.7% of patients experienced side effects. Some background...
Read MoreSearching for patients with advanced prostate cancer to test an experimental medication
In a nutshell This phase 2 study will investigate the safety and effectiveness of AZD4635 in the treatment of metastatic castration-resistant prostate cancer (mCRPC). The main outcome will be the objective response rate (ORR) and prostate-specific antigen (PSA; a marker of prostate cancer) response. This trial is recruiting in multiple...
Read MoreTotal testosterone density as a marker of tumor load in patients with prostate cancer
In a nutshell This study aimed to investigate a new way to evaluate prostate cancer risk, through the total testosterone density (TTD). This study found that TTD can be used to help manage patients with low-risk PCa. Some background Testosterone is a hormone that is made by the testicles. It usually fuels the growth of...
Read MoreEvaluating the safety of re-treatment with radium-223
In a nutshell This study aimed to evaluate the safety and effectiveness of radium-223 (Xofigo, formerly known as Alpharadin) in patients with advanced prostate cancer that has spread to the bones and who have had this treatment previously. This study found that re-treatment with radium-223 was well tolerated and with good results. Some background...
Read MoreSurviving cancer – is there a greater risk of cardiovascular disease long-term?
In a nutshell This study investigated if there is a higher risk of cardiovascular disease (CVD) in cancer survivors. They found that cancer survivors have a higher risk of CVD. Some background Improved cancer detection and treatment has increased the rates of survival. The number of cancer survivors living for more than 10 years is growing. Some...
Read MoreLooking for patients with advanced prostate cancer to test a new treatment
In a nutshell This phase 1/2 trial is examining the effectiveness of treatment with GB1275 alone or in combination with immunotherapy in patients with advanced solid tumors such as prostate cancer. The main outcome to be measured will be dose toxicity and tumor response to the treatment. This study is being conducted in Tennessee and Texas, US. The...
Read MoreSearching for patients with advanced prostate cancer to test a new medication
In a nutshell This phase 2b trial will evaluate ModraDoc006 (MOD) in patients with metastatic castration-resistant prostate cancer (mCRPC). The main outcomes will be the objective response rate (ORR). This trial is recruiting at a number of locations in the US. The details Metastatic castration-resistant prostate cancer (mCRPC) is...
Read MoreLooking for patients with high-risk prostate cancer to test a combination therapy
In a nutshell This study aims to examine the effectiveness of niraparib (Zejula) combined with hormone therapy and radiotherapy to treat patients with high-risk prostate cancer. The main outcome to be measured will be how long patients remain cancer-free. This study is recruiting in Philadelphia, PA. The details Prostate cancer occurs mostly...
Read MoreLooking for patients with prostate cancer to test a combination of radiotherapy
In a nutshell This phase 2 trial will investigate the effectiveness of stereotactic ablative radiation therapy (SABR) and radiopharmaceutical therapy (RPT) in patients with oligometastatic (cancer spread in 1-2 other tissues or organs) prostate cancer. The main outcome will be progression-free survival (PFS). This trial is recruiting in Maryland,...
Read MoreEvaluating enzalutamide plus androgen deprivation therapy to treat metastatic prostate cancer
In a nutshell This study aimed to examine the effectiveness and safety of enzalutamide (Xtandi) with androgen deprivation therapy (ADT) in metastatic prostate cancer. This study found that this combination was associated with longer progression-free and overall survival compared to ADT alone. Some background Patients...
Read MoreSearching for patients with advanced castration-resistant prostate cancer to test a new combination treatment
In a nutshell This phase 1b/2 trial will investigate the safety of cabozantinib (Cabometyx) with atezolizumab (Tecentriq) in patients with advanced solid tumors. The main outcomes will be the maximum tolerated dose (MTD) and overall response rate (ORR). The details Advanced cancers have limited treatment options. Surgery may not be possible....
Read More
